Scinai Immunotherapeutics Ltd. (SCNI) 株式分析

企業概要

Scinai Immunotherapeutics Ltd. is a biopharmaceutical enterprise dedicated to the development, manufacturing, and commercialization of biological products specifically designed to address inflammation and immunology. The company targets the treatment of infectious and autoimmune diseases within the Israeli market, utilizing its proprietary technology to create nanosized VHH antibodies, also known as nanoAbs, which aim to address specific disease mechanisms. This entity operates within the healthcare sector, specifically the biotechnology industry, a field characterized by high R&D expenditures and long development cycles for therapeutic candidates. With a market capitalization of $2.05M and annual revenue of $1.31M, Scinai represents a micro-cap entity with a very small employee base, as specific headcount data is not disclosed. The valuation metrics indicate that the company is trading at a market cap significantly lower than its revenue base, reflecting the typical profile of early-stage biotech firms where cash reserves and future potential often outweigh current profitability.

財務健全性

The company reported trailing twelve-month revenue of $1.31M, yet it incurred a net income of $-8,307,000 and an EBITDA of $-6,121,000, highlighting a substantial negative gap between top-line growth and bottom-line performance. This disparity reveals a highly aggressive cost structure where operational expenses, likely driven by R&D and manufacturing setup costs, far exceed current sales revenue. Free cash flow stands at $-3,408,750, indicating that the company is consuming cash rapidly to fund its operations and development pipeline, which limits immediate financial flexibility but is common for pre-revenue or early-revenue biotech stages. The gross margin is reported at -202.3%, the operating margin at -702.4%, and the profit margin at 0.0%, all of which reflect the intense cost pressures and lack of scale typical for a company where costs have outpaced revenue generation. On the liability side, the company holds $1.66M in cash against $2.27M in debt, resulting in a debt-to-equity ratio of 27.98, which suggests a leveraged balance sheet where liabilities exceed equity holdings. Liquidity is supported by a current ratio of 1.30, meaning current assets exceed current liabilities, providing a buffer for short-term obligations despite the negative cash flow. Return on Equity is -91.9% and Return on Assets is -37.6%, metrics that demonstrate the company is currently generating negative returns on its capital base as it invests heavily in future product potential rather than immediate shareholder value creation.

バリュエーション評価

The trailing P/E ratio and forward P/E ratio are both N/A due to the company's net losses, implying that traditional earnings-based valuation models are not applicable at this stage of the company's lifecycle. The price-to-book ratio stands at 0.39, indicating that the market values the company at less than one-third of its book value, which often signals that investors are pricing in significant risks or limited tangible assets relative to equity. The price-to-sales ratio is 1.56, while the EV/EBITDA is -1315.56, suggesting that valuation is being assessed primarily on revenue multiples rather than earnings power or enterprise value multiples. The stock has traded between a 52-week high of $6.18 and a 52-week low of $0.55, and without the specific current price, the exact percentage below the high cannot be calculated, but the wide range indicates high volatility typical of small-cap biotech stocks. The beta value is N/A, meaning there is insufficient data to quantify the stock's volatility relative to the broader market index, though the wide price range suggests significant price swings. These alternative metrics provide a more comprehensive view of a loss-making company's valuation than standard earnings multiples, focusing instead on revenue generation and asset backing.

Growth & Income

Revenue growth year-over-year is 30.6%, while earnings growth is N/A due to continued losses, indicating that top-line expansion is currently the primary driver of the company's trajectory rather than profitability improvement. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, reflecting a strategy where earnings are reinvested into research and development rather than distributed to shareholders. The absence of a dividend yield confirms that the company is not generating sufficient free cash flow to support shareholder distributions, a standard practice for growth-oriented biotechnology firms. The overall growth and income profile is characterized by strong revenue acceleration coupled with significant cash burn and no current income distribution to investors.